Format

Send to

Choose Destination
J Control Release. 2014 Nov 28;194:238-56. doi: 10.1016/j.jconrel.2014.09.001. Epub 2014 Sep 7.

Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Author information

1
Department of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA.
2
Department of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA; Preclinical Nuclear Imaging Laboratory, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 USA.
3
Department of Pharmaceutical Science, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hilo, HI, USA; Natural Products and Experimental Therapeutics Program, University of Hawaii Cancer Center, Honolulu, HI, USA. Electronic address: mahavir@hawaii.edu.

Abstract

Chemotherapeutic agents have certain limitations when it comes to treating cancer, the most important being severe side effects along with multidrug resistance developed against them. Tumor cells exhibit drug resistance due to activation of various cellular level processes viz. activation of drug efflux pumps, anti-apoptotic defense mechanisms, etc. Currently, RNA interference (RNAi) based therapeutic approaches are under vibrant scrutinization to seek cancer cure. Especially small interfering RNA (siRNA) and micro RNA (miRNA), are able to knock down the carcinogenic genes by targeting the mRNA expression, which underlies the uniqueness of this therapeutic approach. Recent research focus in the regime of cancer therapy involves the engagement of targeted delivery of siRNA/miRNA in combinations with other therapeutic agents (such as gene, DNA or chemotherapeutic drug) for targeting permeability glycoprotein (P-gp), multidrug resistant protein 1 (MRP-1), B-cell lymphoma (BCL-2) and other targets that are mainly responsible for resistance in cancer therapy. RNAi-chemotherapeutic drug combinations have also been found to be effective against different molecular targets as well and can increase the sensitization of cancer cells to therapy several folds. However, due to stability issues associated with siRNA/miRNA suitable protective carrier is needed and nanotechnology based approaches have been widely explored to overcome these drawbacks. Furthermore, it has been univocally advocated that the co-delivery of siRNA/miRNA with other chemodrugs significantly enhances their capability to overcome cancer resistance compared to naked counterparts. The objective of this article is to review recent nanocarrier based approaches adopted for the delivery of siRNA/miRNA combinations with other anticancer agents (siRNA/miRNA/pDNA/chemodrugs) to treat cancer.

KEYWORDS:

Cancer; Clinical trial; Combination therapy; Nanotechnology; miRNA; siRNA

PMID:
25204288
PMCID:
PMC4254052
DOI:
10.1016/j.jconrel.2014.09.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center